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The hypoxia-inducible transcription factor (HIF) co-ordinates the response of tumours to low oxygen by
stimulating genes involved in metabolism and angiogenesis. HIF pathway activation is associated with
decreased progression-free survival and increased mortality; compounds that target this pathway are
potential agents for the treatment of a range of solid tumour malignancies. Renal cancers are likely to be
particularly sensitive to inhibition of the HIF pathway since,80% show constitutive activation of HIF. We
have previously described the di-substituted naphthalene derivative, CL67, which binds to a G-quadruplex
higher-order structure in the HIF promoter sequence in vitro. We show here that CL67 blocks HIF
expression leading to inhibition of HIF-transactivation and down-regulation of downstream target genes
and proteins in renal carcinoma cell lines and in amouse xenograft model of renal cancer. This inhibition is
independent of pathways that control HIF abundance through oxygen-dependant degradation and oxygen
dependant HIF sub-unit expression.
A
reas of reduced oxygen availability (hypoxia) are found in all solid tumours where rapid cellular prolif-
eration without concomitant vascularisation produces a spatially and temporally heterogeneous blood
supply1. To meet their increasing metabolic demands and enable growth and progression, tumours must
ultimately develop their own vasculature. This process, known as angiogenesis, is one of the hallmarks of cancer
and is co-ordinated largely by the pattern of gene expression brought about by hypoxia-inducible factor (HIF) in
response to low oxygen levels2,3. Levels of HIF are elevated in a number of human cancers, an observation that is
linked to increased progression and mortality, making inhibitors of the HIF pathway attractive targets for the
development of new anti-cancer therapeutics4.
HIF-1 is a heterodimer consisting of a constitutively expressed HIF-1b subunit and an oxygen-dependent HIF-
a subunit that together bind specific hypoxia response element (HRE: 59-(A/G)CGTG-39) sequences in promoters
of their target genes5. There are three a isoforms; HIF-1a plays a general role in hypoxia signaling while HIF-2a
and HIF-3a show a more context specific pattern of expression6,7. Control of HIF levels and activity is achieved
through expression and degradation of the a subunits by oxygen dependent and independent mechanisms
(Fig. 1a). The principal oxygen-dependant control of HIF levels is mediated by the von Hippel Lindau (VHL)
protein. In normoxia (21% oxygen), conserved prolines 402 and/or 564 are hydroxylated by prolyl hydroxylase
domain (PHD) enzymes which require O2 as a substrate. Hydroxylated HIF-a subunits are recognised by VHL
which in turn recruits an ubiquitin ligase complex via Elongin C, directing HIF-a to proteosomal degradation8.
Under continuous hypoxia, HIF-a subunits remain un-hydroxylated, are not recognised by VHL and can there-
fore form stable heterodimers with HIF-1b subunits. Dimerised HIF proteins are then able to bind their cognate
HREs and co-ordinate the transcription of pro-angiogenic growth factors such as vascular endothelial growth
factor (VEGF), as well as numerous genes that contribute to cancer progression including Angiopoietin-like 4
(ANGPTL4)9. In the absence of prolyl hydroxylation (i.e. in an oxygen independent manner) the RACK1 protein
can also interact with HIF-a to recruit Elongin C leading to HIF ubiquitylation and proteolysis. This interaction is
inhibited by HSP90 which competes with RACK1 for the same binding site on HIF-1a10. Cellular levels of active
HIF are also stimulated by the phosphatidylinositide-3-kinase(PI3K)/AKT/mammalian target of rapamycin
(mTOR) and mitogen-activated protein kinase (MAPK) pathways that converge on p70 S6 kinase and eIF-4E
binding proteins, leading to increased translation of HIF-a mRNAs11–13.
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Figure 1 | Regulation of the HIF pathway by oxygen dependant and independent mechanisms (a) Under normoxia, prolyl hydroxylase domain proteins
use oxygen and a-ketoglutarate as substrates to hydroxylate conserved proline residues on HIF-a subunits. This allows binding of the VHL protein which
recruits an ubiquitin ligase complex via Elongin C, leading toHIF-a ubiquitination and proteosomal degradation8. Oxygen-independent control ofHIF is
mediated by RACK1 which also recruits Elongin C and directs the HIF-a subunits to the proteasome. PI3K/AKT/mTOR and MAPK pathways can
increase translation of HIF-amRNA in an oxygen-independent manner11. In hypoxia, stabilised HIF-a subunits dimerise with HIF-b subunits enabling
interaction withHREs in a wide range of gene promoters in the nucleus. The resulting pattern of transcription drives cellular responses to hypoxia such as
angiogenesis andmetabolic reprogramming, and can up-regulate the expression ofmultiple genes that contribute to cancer progression through survival,
metastasis and invasion13. (b) Structure of CL67.
www.nature.com/scientificreports
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Genetic and immunohistochemical analyses of different popula-
tions have reported between 50% and 91% of familial and sporadic
renal cell carcinomas are associated with genetic or epigenetic abnor-
malities within VHL that cause loss of function and are associated
with increased expression of HIF-1a and HIF-2a14–19. Constitutive
expression of theHIF pathway is commonly regarded as the foremost
oncogenic cause of renal cancers and inhibitors of the HIF pathway
are likely to be particularly effective in treating renal cell carcinoma.
Current molecular strategies to inhibit the HIF pathway include
direct inhibition of HIF-1a using anti-sense RNA20, blockage of
HIF-1a/HIF-1b dimerization21 and re-purposing of existing antic-
ancer agents that inhibit components of the PI3K/AKT/mTOR and
MAPK22–25. While most work has focused on targeting the HIF-1a
subunit, HIF-2a is also commonly up-regulated in renal cancers26,
where it is specifically responsible for the up-regulation of pro-
tumorigenic genes27,28.
Our laboratory’s approach to the discovery of HIF inhibitors
involves targeting promoter sequences containing several short runs
of guanine nucleotides that can form complex higher order struc-
tures, termed quadruplexes29. The highly distinctive nature of quad-
ruplex topologies suggests that they can act as novel therapeutic
targets, for example in the selective inhibition of transcription of a
given oncogene, using designed small molecules to stabilise a par-
ticular quadruplex30. The promoters of both HIF-1a and HIF-2a
contain guanine-rich sequences capable of forming a G-quadruplex
structure one of which has been shown tomodulate the activity of the
HIF-1a promoter (59 – GCGCGG4AGG4AGAG5GCG3AGCGCG –
39), though the role of potential G-quadruplex sequences within the
HIF-2a promoter is unknown31,32.
We have identified the G-quadruplex stabilising agent CL67
(Fig. 1b) as a potent and selective inhibitor of renal carcinoma cells
in vitro compared to other cancer cell lines including breast, prostate,
pancreatic and lung cancer cells33. Here we show that CL67 inhibits
both HIF-1a and HIF-2a proteins in a dose- and time-dependent
manner both in vitro and in vivo leading to inhibition of HIF-1
transactivation and reduced transcription of downstream target
genes.
Results
CL67 inhibits the HIF pathway in renal cancer cell lines.We have
recently shown that CL67, a DNA quadruplex-stabilising disub-
stituted naphthalene derivative, selectively inhibits the growth of
renal and osteosarcoma cell lines. In U20S osteosarcoma cells this
activity is accompanied by a reduction ofHIF-1a andHIF-2a protein
levels33. To assess whether CL67 also inhibits the HIF pathway in
renal cancer cells, HIF and VEGF protein levels and hypoxia
response element (HRE) transactivation were measured in renal
clear cell carcinoma lines RCC4 and 786-0 following compound
exposure (Fig. 2).
A dose- and time-dependent decrease in HIF-1a abundance was
observed in RCC4 cells in both normoxic and hypoxic conditions
(Fig. 2a). Levels of HIF-1a protein in hypoxic RCC4 cells were
reduced to 50% of untreated control levels within 2 h of treatment
with 53 IC50 of CL67 and reached maximal inhibition (12% of
untreated control) after 4 h treatment. There was a marked recovery
of HIF-1a levels by 8 h post exposure indicating that this HIF inhibi-
tion is reversible. In hypoxic 786-0 cells increasing concentrations of
CL67 resulted in a steady decrease (to 61%, 51% and 37% of
untreated controls after 4 h treatment with 13, 53 and 103
IC50CL67, respectively) of the HIF-2a protein (Fig. 2a). It should
be noted that 786-0 cells constitutively express HIF-2a but do not
express HIF-1a34. No change in the levels of HIF-1b was detected in
either cell line.
To confirm the functional relevance of the reduced HIF protein
expression, we tested whether CL67 treatment reduced HIF-
mediated trans-activation of the HRE using a luciferase reporter
construct. In untreated cells HRE trans-activation was increased to
236% of normoxic levels by exposure to hypoxia for 4 h (Fig. 2b).
CL67 treatment produced a dose-dependent decrease in HIF activity
in RCC4 cells under both normoxic and hypoxic conditions. HRE
activity was reduced to approximately baseline (normoxic) levels by
4 h treatment with 13 IC50 CL67 under continued hypoxia and this
was significantly reduced to 23.4% and 14.8% of hypoxic untreated
control levels by treatment with 53 and 103 IC50 CL67, respectively
(p , 0.01). HIF trans-activation was not significantly reduced by
treatment with 13 IC50 CL67 under normoxia but was significantly
decreased by treatment with 53 and 103 IC50 CL67 (59% and 25%
respectively; p , 0.01). CL67 did not have a significant effect on
trans-activation of the pGL3 control vector, which lacks the HRE.
Further confirmation of the functional relevance of decreased HIF
protein levels was determined bymeasuring the effect of CL67 on the
abundance of the HIF down-stream target, VEGF, using ELISA
(Fig. 2c). CL67-treated RCC4 cells showed a significant dose- and
time-dependent reduction in VEGF abundance (71.6% that of
untreated controls within 4 h of treatment with 53 IC50; p, 0.01).
Together these results demonstrated the functional relevance of
CL67-mediated inhibition of HIF production, showing that reduced
HIF protein levels resulted in reduced activity from HIF-inducible
promoters and reduced expression of HIF target proteins.
CL67 inhibits the HIF pathway independently of VHL and
upstream oncogenic signalling pathways. Cellular levels of HIF-
1a are controlled principally by oxygen-dependant degradation
mediated by VHL and oxygen-independent protein synthesis
controlled through PI3K-AKT-mTOR and MAP kinase activa-
tion13,34,38. To determine if inhibition of HIF by CL67 was achieved
through disruption of these pathways, colony formation and the
abundances and activities of key members of each pathway were
assessed in VHL positive and negative RCC4 cells treated with
CL67 (Fig. 3).
RCC4 cells were stably transfected with wild type VHL and
exposed to 53 IC50 CL67 under either normoxic or hypoxic condi-
tions. In normoxic cells, restoration of active VHL resulted in a
depletion of HIF-1a. This effect was reversed in hypoxic conditions
confirming the functionality of the transfected VHL (Fig. 3b). CL67
significantly reduced colony formation in both RCC4 and RCC4/
VHL cells after 4 h treatment with 5 3 IC50 and 103 IC50 CL67 in
both normoxia and hypoxia (Fig. 3a). Furthermore, a time-depend-
ent reduction of HIF-1a protein levels was observed in both
normoxic VHL 2/2 cells (Fig. 3b) and in hypoxic cells carrying
wild-type VHL (Fig. 3c). These results demonstrate that CL67 does
not depend on the VHL pathway to inhibit colony formation, and
that CL67 inhibits HIF-1a protein levels by a VHL-independent
mechanism.
No significant difference in colony formation was seen in VHL
negative RCC4 cells in hypoxia compared to normoxia. Interestingly
however, RCC4/VHL cells were significantly less sensitive to CL67
than VHL negative RCC4 cells and were significantly more sensitive
to CL67 in hypoxia compared to normoxia (Fig. 3a). The restoration
of active VHL also increased IC50 values for CL67 in RCC4, RCC10
and 786-0 renal cell lines (Supplementary Figure S1). Taken together
these observations indicate that increasing HIF levels may in fact
potentiate the anti-proliferative activity of CL67.
Maximum reduction in HIF-1a levels were observed after 4 h
treatment in both VHL positive and negative cell lines. However,
protein levels in both lines recovered to between 85% and 91% of
the untreated control by 8 h, indicating that the compound is either
inactivated (e.g. through metabolism or degradation), or that the
CL67-mediated inhibition of HIF production is circumvented by
activation of alternate pathways. We therefore measured the abund-
ance of three key proteins, HSP90, AKT and Raf-1, which act in
upstream HIF activation pathways (Fig. 3c). None were affected by
www.nature.com/scientificreports
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CL67 treatment in RCC4 cells. In addition, a panel of 65 kinases,
including PI3K, MAPK and mTOR, tested negative (IC50. 10 mM)
for inhibition by CL67 (experiments performed by Novartis
Institutes for Biomedical Research). A description of the assessed
kinases is given in Supporting Table S1. These results indicate that
CL67 inhibits HIF independently of both oxygen-dependant and
oxygen-independent signalling pathways that are known to control
its cellular levels and activity, as well as independently of multiple
oncogenic signalling pathways.
CL67 inhibits the expression of HIF-1a and HIF-1 regulated
genes. We have demonstrated in vitro that CL67 binds to and
stabilises a G-quadruplex sequence located within the promoter
sequence of HIF-1a33. We therefore hypothesised that CL67
inhibits the HIF pathway by preventing transcription of the gene
as a consequence of stabilising the promoter G-quadruplex
sequence. To test this we analysed the mRNA abundance of HIF-
1a by qRTPCR using two sets of HIF-1a primers. Using the first
primer, set treatment of RCC4 cells with 13, 53, and 103 IC50 of
CL67 reduced HIF-1a mRNA abundance to 29.2%, 29.2%, and
27.3% that of the untreated controls respectively (p , 0.05,
Student’s t-test). In a separate time course, exposure of RCC4 cells
to 53 IC50 of CL67,HIF-1amRNA levels were reduced to 3.9%, 4.0%
and 4.2% of the corresponding untreated control after 2, 4 and
6 hours (p , 0.05). In contrast, measurement of the HIF-2a
transcript in 786-0 cells by qRTPCR revealed a modest reduction
in expression to between 92.5% and 91.4% that of the untreated
control following 4 hours exposure to 53 IC50 CL67.
Figure 2 | CL67 inhibits the HIF pathway. (a) Effect of CL67 onHIF protein expression levels in renal cancer cell lines. Left-hand panel: RCC4 cells were
incubated in normoxia (21% oxygen) and 786-0 cells in hypoxia (1% oxygen), for 4 h, with the indicated doses of CL67. Right-hand panel: RCC4 cells
were treated with five times the IC50 of CL67 for the indicated times. Cells were then lysed andWestern blotting was performed probing for HIF-1a, HIF-
2a, HIF-1b. Lamins A and C were probed as loading controls. Results are representative of at least 2 independent experiments. (b) CL67 inhibits
transcription from the hypoxia response element (HRE). RCC4 cells were co-transfected with either an empty vector control (pGL3; grey bars) or a vector
expressing luciferase under the control of multiple copies of the (HRE; red bars). To normalize for transfection efficiency both sets of cells were
transformed with a vector expressing renilla luciferase. Cells were then exposed to either normoxia or hypoxia and treated for 4 h with the indicated
dosages of CL67. Luciferase activity was measured as described in Methods and final results were expressed as a percentage of the activity of untreated,
normoxic cells. (c) CL67 treatment reduces VEGF protein levels in a time- and dose- dependant manner. RCC4 cells were exposed to CL67 at 53 the IC50
for 0, 2 and 4 h (left-hand panel), or for 4 h at 0, 13, 53, and 103 the IC50 (right-hand panel) Samples (1 ml) of the culture mediumwere then collected
and VEGF levels were measured using ELISA. VEGF levels in all treated samples were significantly reduced compared to untreated controls (p# 0.01).
Data in (b) and (c) show the mean 6S.D. of three experiments carried out with at least 2 replicates. Note that cropped blots are shown here.
www.nature.com/scientificreports
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TheHIF-1 pathway is amajor regulator of angiogenesis in hypoxic
tumours39. As a second assessment ofHIF-1 pathway blockage and of
HIF-1a transcriptional inhibition we measured the expression of 83
genes involved in angiogenesis, in normoxic RCC4 cells. This gene
set included HIF-1a (measured with a different primer set than the
first experiment), 15 genes that have been robustly shown to be under
the control of HIF-1, a further 9 genes that have been linked to the
HIF pathway but not demonstrated to be under HIF-1 control, and
59 genes that have not been linked to HIF-mediated regulation. The
full gene list and dataset for this analysis is given in Supporting Table
S2.
There was a titratable decrease in HIF-1a mRNA abundance in
normoxic RCC4 cells exposed to 53 IC50 of CL67 for 2 h, 4 h or 6 h
compared with untreated cells at 0 h (Fig. 4a). However, in contrast
to the first qPCR assay, none of these decreases were strong or stat-
istically significant. Transcripts for all of the 15 genes that are
induced by HIF-1 were decreased in abundance over the course of
the experiment. The most heavily down-regulated genes were those
encoding ANGPTL4, FN1, PLAU and VEGFA, all of which showed
statistically significant down-regulation at 6 h exposure (Fig. 4b).
Within the angiogenesis gene set there was also a significant reduc-
tion in the expression of the 15 HIF-regulated genes compared with
the 59 HIF-1 independent genes (Fig. 4c, Supplementary Table S2),
indicating that the majority of the observed transcriptional changes
were a result of HIF pathway inhibition. Interestingly, there was also
a significant down-regulation of the genes encoding tumour necrosis
factor-a (TNFa), the chemokines CXCL1 and CXCL6, and the inter-
leukins IL6 and IL8, none of which have previously been shown to
be under control of HIF-1 (Fig. 4d). This suggested that these genes
could be as yet unidentified targets of theHIF pathway. Alternatively,
they could be additional drug targets that are directly inhibited by
CL67.
These results further demonstrate that CL67 is a robust inhibitor
of the HIF pathway in renal cancer cell lines, inhibiting expression of
Figure 3 | CL67 inhibits colony formation and HIF-1a in a manner independent of VHL and the PI3K/AKT/mTOR and MAPK pathways. (a) RCC4
cells (lacking VHL; RCC4) and RCC4 cells stably transfected with VHL (RCC4/VHL) were incubated for 4 h with the doses indicated of CL67 in normoxia
(20% oxygen) or hypoxia (1% oxygen). Colony formation assays were then performed. Data represents the mean 6S.D. of 3 experiments with at least 2
replicates. *, Significant difference compared to untreated control (p, 0.01); **, Significant difference compared to both normoxic sample and untreated
sample (p, 0.01). (b and c) RCC4 cells (pVHL 2/2) and RCC4 cells stably transfected with pVHL were incubated with 53 IC50 doses of CL67 for the
indicated times in normoxia or hypoxia. RCC4/VHL cells were exposed to hypoxia for 16 h to increase levels of HIF-1a before treating with CL67. Cells
were lysed andWestern blotting was performed probing for HIF-1a (b), HSP-90, Raf-1 andAKT (c). Actin or lamin Awere used as loading controls. Data
are representative of at least 2 independent experiments. Note that cropped blots are shown here.
www.nature.com/scientificreports
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HIF-regulated genes. This data also indicates that CL67 inhibits the
HIF pathway at least in part by inhibiting transcription of HIF-1a,
though given the variability of the reduction in the HIF-1a transcript
between experiments, other possible mechanisms of inhibition can-
not be fully ruled out.
CL67 inhibits the HIF pathway in vivo. We confirmed the in vivo
relevance of the HIF inhibitory activity of CL67 by measurement of
the expression of both HIF-2a and GLUT-1 proteins in 786-0 cells
grown as xenografts on nude mice (Fig. 5). Both proteins were
significantly reduced within 6 h of treatment with 15 mg/kg CL67.
HIF-2a protein was further reduced to 13.8% of control levels (p ,
0.01) after 8 h and GLUT-1 protein to 9.3% of control levels after
16 h (p, 0.01), further confirming the physiological relevance of the
HIF inhibitory activity of CL67. As seen in with cultured cells, levels
of HIF-2a protein eventually recovered, here after 16 h treatment.
RCC4 and RCC4VHL cells could not be grown as xenografts and
786-0 cells do not express HIF-1a so expression of this protein was
not assessed in this experiment.
Discussion
Up to 91% of renal cancers over-express HIF-1a due to inactivation
of VHL14–19 and are therefore likely to be over-reliant on this pathway
for their genesis, growth and survival.We have previously shown that
CL67 is a novel small molecule inhibitor that preferentially inhibits
renal cancer cell line growth compared to other cancer cell lines
including human breast, lung, prostate and pancreatic cell lines33.
Figure 4 | CL67 inhibited the expression of HIF-1a and HIF-1 regulated genes. (a), (b) and (d)Total RNAwas purified from RCC4 cells exposed to 53
the IC50 of CL67 for 2, 4 or 6 hours, reverse transcribed to cDNA and then used tomonitor the expression changes of 83 genes involved in angiogenesis by
qPCR. Expression data for each gene was normalised to the housekeeping gene RPLP0 and then to untreated samples at t0 (n 5 3; error bars, 90%
confidence interval; *, p, 0.05 and **, p, 0.01 compared with untreated control using Student’s t-test). (c) HIF-1 regulated angiogenesis pathway genes
were significantly down-regulated byCL67 compared toHIF-1 independent genes. Shown are box andwhisker plots of log2 fold expression changes for 59
genes that are not controlled by the HIF-1 pathway (Non-HIF-1) and 15 genes that are established targets of HIF-1 (HIF-1). Significance values are for 2-
tailed, homoscedastic t-tests comparing non-HIF-1 and HIF-1 regulated genes at each time point.
www.nature.com/scientificreports
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These studies also demonstrated that CL67 binds to, and stabilises
G-quadruplex sequences in the HIF-1a and HIF-2a promoter
sequences in vitro, using surface plasmon resonance33. The current
study provides the first evidence that a small molecule G-quadruplex
stabilising agent can produce inhibition of both HIF-1a and HIF-2a
proteins with subsequent down-regulation of the HIF pathway.
Renal cell carcinoma cells exposed to CL67 displayed decreased
levels of HIF-1a and HIF-2a proteins and decreased transactivation
of the phosphoglycerate kinase HRE in both normoxia and hypoxia,
and in both the presence and absence of VHL (Fig. 2 and Fig. 3),
demonstrating a robust inhibitory effect that is likely to be independ-
ent of both tumour oxygen status and VHL. Down-stream target
proteins of theHIF pathway, VEGF andGLUT-1were also decreased
following drug treatment. Though VEGF protein levels were not
reduced to as great an extent as HIF-1a and HIF-2a proteins or
HRE trans-activation, the values obtained were comparable with
previous studies that have shown similar effects on VEGF levels
following inhibition of HIF-1 and which were attributed to VEGF
production through compensatory HIF-independent mechanisms40.
A qPCR array analysis of angiogenesis pathway genes revealed that
CL67 also significantly down-regulated HIF-regulated genes com-
pared with genes that are not under HIF control. Amongst the genes
down-regulated by CL67 were ANGPTL4, EDN1 and VEGFA, all of
which contribute to cancer progression13. Interestingly, pro-inflam-
matory cytokines IL6 and TNFa were also significantly down-regu-
lated in a time-dependent manner by CL67 treatment. Activation of
the IL6 receptor is known to induce HIF-1a expression41, indicating
that the observed IL6 transcriptional inhibition could be linked with
CL67-mediated blockage of the HIF pathway.
Several signalling pathways are known to regulate HIF activity,
andmodulation of these can account for the down-regulation of HIF
by small molecules. For example, inhibitors of HSP90 induce HIF-1a
ubiquitination via RACK1 leading to protein degradation even in the
absence of VHL (Fig. 1a10,42). HSP90 levels in RCC4 cells were un-
affected by the CL67 dosages and exposure times that resulted in
depletion of HIF-1 proteins. Similarly, CL67 did not affect the
expression of Raf-1 and AKT, key members of the MAPK and
PI3K/AKT/mTOR pathways respectively that control HIF-1a pro-
tein expression44, nor did they inhibit the activity of a kinase panel.
Though we cannot fully rule out other non-specific effects, the cur-
rent data support the conclusion that CL67 is a specific and direct
inhibitor of the HIF pathway.
In interesting observation was the decreased capacity of CL67 to
inhibit colony formation and in vitro growth of renal carcinoma cells
in which active VHL had been restored (Fig. 3a and supplementary
data). Due to inactive VHL, RCC4 cells express high levels of HIF-1a
in both normoxia and hypoxia. The differential effects of CL67 on
VHL-positive and VHL-negative cell lines therefore indicate that
increased HIF expression potentiates the anti-proliferative activity
of CL67, and therefore has positive implications for the ability of this
compound to selectively inhibit the growth of carcinomas in which
the HIF pathway is over-active.
There was a notable discrepancy between the qPCR data obtained
using a qPCR array, which showed a titratable but insignificant
decrease in HIF-1a mRNA (Fig. 4a) and the values obtained using
specific qPCR primers that indicated a strong and significant down-
regulation of HIF-1amRNA (reduced to between 3.9% and 29.2% of
untreated control). Furthermore, HIF-2a mRNA in 786-0 cells was
not significantly reduced despite strong down regulation of HIF-2a
protein in 786-0 tumour xenografts (Fig. 5). We cannot therefore
safely conclude that CL67 acts as a transcriptional inhibitor of HIF-
1a or HIF-2a. One alternative explanation is that stabilisation of an
RNA G-quadruplex within the HIF-1a 59UTR could be responsible
for the drop in protein levels. This mechanism would be consistent
with the recovery of HIF levels we observed both in cells and in vivo
as the continued production of HIF transcripts could titrate out
cellular CL67, allowing subsequent restoration of expression. These
questions will drive future work into the molecular mechanism of
CL67.
TheHIF-1a promoter contains a polypurine/polypyrimidine tract
(265 to 285), which has been previously identified as forming a
parallel, intramolecular G-quadruplex31. Site-directed mutagenesis
of this region markedly reduces HIF-1a transcriptional activity,
whilst two G-quadruplex ligands, telomestatin and TmPyP4, have
been shown to bind and stabilise the G-quadruplex formed by the
HIF-1a polypurine sequence31. Interestingly, it was also noted that
the HIF-2a promoter contains a nearly identical polypurine/poly-
pyrimidine tract which appears capable of forming an intramolecular
G-quadruplex. Our current data together with previous work33 sug-
gests, though does not prove, that G-quadruplex in both HIF-1a and
HIF-2a are targeted by CL67, and further studies are needed to
elucidate the precise mechanisms and targets involved. However,
since the polypurine/polypyrimidine tract that is likely to be able
to form an intramolecular G-quadruplex differs from the HIF-1a
quadruplex sequence by only two bases31, it seems likely (though
not proven) that the inhibition of HIF-2a observed in the current
study is also a result of CL67 binding to a G-quadruplex sequence in
HIF-2a. In addition, the polypurine tract involved in G-quadruplex
formation contains binding sites for the activating transcription
Figure 5 | CL67 inhibits the HIF pathway in vivo. (a) 786-0 cells were
grown as xenografts in the flanks of nude mice. Once the xenografts had
reached an appropriate size (median 150 mm3) mice were treated with
15 mg/kg CL67. Tumours were harvested from four mice at each time
point and were immediately homogenised and lysed on ice. Western
blotting was then performed with antibodies against HIF-2a, GLUT-1,
lamin A and lamin C. Representative blots for two of the four mice at each
time point are shown. A common sample from the untreated control
group was run on each gel as a reference to enable comparison between
gels. (b) Blots were quantified using ImageQuant Software, normalised for
loading and expressed as a percentage of the intensity of the common
reference sample (Data are means 6 s.e.; n5 4, *, p, 0.05 compared with
the control group). Note that cropped blots are shown here.
www.nature.com/scientificreports
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factors Sp1 and AP231 and we cannot rule out that CL67 may affect
their binding thereby altering transcription of HIF-1a and HIF-2a.
However, our data demonstrating that CL67 inhibits both HIF-1a
and HIF-2a mRNA, in addition to the data showing that CL67 acts
independently of the VHL, PI3K/AKT/mTOR andMAPK pathways,
provides additional evidence that CL67 inhibits the HIF pathway via
a novel mechanism distinct from any previous HIF inhibitor.
It is thought that HIF-1a and HIF-2a may play different roles in
the cellular response to hypoxia and nutrient deprivation depending
on their cellular environment and that their responses may be some-
what cell specific43. Interestingly, the expression of both HIF-1a and
HIF-2a varied within the cell lines used during this study but the
effect on the downstream HIF pathway (transactivation and down-
stream gene expression) after inhibition of HIF-1a and HIF-2a by
CL67 was similar. CL67 also inhibits cell growth to a similar extent in
a panel of renal cell lines with varying expression of HIF-1a andHIF-
2a (IC50 values of 1.4–2.6 mM)33. Long-term growth studies in ani-
mal models may help to elucidate the relative effects of inhibition of
HIF-1a and HIF-2a more fully.
In summary, we have identified CL67 as a potent inhibitor of the
HIF pathway which we propose acts by binding to and stabilising G-
quadruplex structures in HIF-1a and HIF-2a leading to decreased
transcription, down-regulation of HIF-1a and HIF-2a proteins, and
inhibition of HIF transactivation with subsequent reduction in
expression of down-stream target genes, both in vitro and in vivo.
In addition, the compound also down-regulates expression of pro-
inflammatory cytokine IL6. CL67 therefore represents an exciting
therapeutic agent, with a novel mechanism of action, which may
offer therapeutic advantage in the treatment of human renal cancers.
Methods
Cell culture and drug treatments.A498 and 786-0 human renal carcinoma cells were
obtained from ATCC. RCC4 and RCC4VHL (RCC4 cells transfected with the
functional VHL gene34,35) human renal carcinoma cells were obtained from the
European Collection of Cell Cultures. Cells were cultured as recommended by
suppliers in either DMEM, MEM or RPMI supplemented with 2 mM glutamine and
10% Foetal Bovine Serum. RCC4 and RCC4VHL cells were also maintained in
0.5 mg/ml G418 (Invitrogen). Growth and drug treatments were performed in
humidified air, 21% O2, 5% CO2, 74% N2 (normoxia) or 1% O2, 5% CO2, 94% N2
(hypoxia) using an In Vivo Hypoxia Workstation 400 (Ruskinn, UK). Analytically
pure CL67 was dissolved in DMSO. Cells treated with CL67 at increasing
concentrations (13, 53 or 103 IC50) and/or exposure times (0 to 8 h) were washed
in ice-cold PBS, harvested by scraping into 10 ml ice-cold PBS and collected by
centrifugation (300 g, 3 min, 4uC) prior to re-suspension into the relevant assay
buffer. IC50 values for CL67, reported previously33 were 1.4 mM in RCC4 cells and
2.3 mM for 786-0 cells.
Western blotting. Western blotting was performed as described previously36 using
mouse anti-human HIF-1a (15250; Transduction Labs), HIF-2a goat anti-human
HIF-1b (15200; Santa Cruz), goat anti-human lamin A/C (15500; Santa Cruz), rabbit
anti-human AKT (151000; Cell Signalling Technology), rabbit anti-human HSP90
(151,000; Santa Cruz), goat anti-human actin (151,000; Santa Cruz), mouse anti-
human Raf-1 (151,000; Santa Cruz) and mouse anti-human GLUT-1 (15200; Santa
Cruz). All blots were incubated in primary antibodies overnight at 4uC with shaking.
Appropriate secondary antibodies were used at 155,000 (1 h, room temperature with
shaking). Blots were quantified using ImageQuant software (Molecular Dynamics).
Luciferase reporter assays.A pGL3 firefly luciferase reporter plasmid containing the
phosphoglycerate kinase HRE was supplied by Professor P. Maxwell (University
College London, UK)34. The empty pGL3 control plasmid and the pRL-CMV Renilla
luciferase plasmids were obtained from Promega. Cells were transfected with the
pRL-CMV Renilla luciferase plasmid and either the HIF-1 reporter plasmid or the
pGL3 control plasmid using LipoTAXI (Stratagene) and 24 h later were exposed to
normoxia or hypoxia for the required time, with or without CL67. Firefly and Renilla
luciferase activities were measured using the Dual Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions.
VEGF measurements. Approximately 107 cells were treated with CL67 as required.
1 mL of cell culture medium was removed and cleared using centrifugation
(1,500 r.p.m., 4uC, 3 min). The supernatant was stored at 280uC prior to use. VEGF
abundance was quantified using a human VEGF ELISA kit according to the
manufacturer’s instructions (R&D Systems, Minneapolis, MN).
Clongenicity assays. RCC4 cells (lacking VHL; RCC4) and RCC4 cells stably
transfected with VHL (RCC4/VHL) were incubated for 4 h with the doses indicated
of CL67 in normoxia (20% oxygen) or hypoxia (1% oxygen) in T-25 flasks containing
5 mlmedium. Cells were then washed three times in 10 ml PBS and trypsinised using
standard protocols. 100, 500 and 1,000 cells were plated in duplicate into 6-well plates
containing 10 ml medium and were incubated in normoxia for 14 days. Cells were
then washed three times in 10 ml PBS, fixed using 5 ml 70% ethanol, and colonies
containing.50 cells were counted after staining (2%methylene blue in 50% ethanol,
2 ml). Results were expressed as a percentage of untreated controls and represent the
mean of three experiments carried out in duplicate.
Reverse transcriptase PCR (RT-PCR). Total RNA was isolated from approximately
107 cells using the RNeasy kit (Qiagen, Crawley, UK) according to the manufacturer’s
protocol. HIF-1a transcripts were quantified using two-step, quantitative real time
PCR (qRTPCR). First-strand cDNA synthesis was performed for each sample with a
Protoscript M-MuLV Taq RT-PCR kit (New England Biolabs, MA, USA) using 1 mg
total RNA and oligo-dT primers. qPCR was performed using Stratagene Brilliant III
SYBR Green master mix in a Stratagene MX-3000P instrument (Agilent, TX, USA)
according to the manufacturer’s instructions using 2 ng input cDNA and primers at
300 nM. The following primer sequences were used: HIF-1a forward: CCAGTTA-
CGTTCCTTCGATCAGT; HIF-1a reverse: TTTGAGGACTTGCGCTTTCATCA,
HIF-2a forward: AAGCCTTGGAGGGTTTCATTG, HIF-1a reverse: TGCTGA-
TGTTTTCTGACAGAAA, b-actin forward: CCCAGAGCAAGAGAGG, b-actin
reverse: GTCCAGACGCAGGATG. Duplicate biological samples were measured in
duplicate for each gene, then fold-regulation relative to the untreated control was
determined using the Relative Expression Software Tool–384, version 237. Samples
were normalised to b-actin. Differences in PCR efficiency were normalised using
relative standard curves of cDNA pooled from all samples. P-values were determined
for 2000 randomisations.
Angiogenesis pathway analysis. The expression of 83 genes involved with
angiogenesis was assessed using human angiogenesis PCR arrays (SABiosciences).
Total RNA was extracted from CL67-treated cells using the RNeasy kit with on-
column DNaseI treatment (Qiagen) according to the manufacturer’s protocol. The
quality of the harvested RNA was confirmed by nanodrop spectroscopy and by
analysis with a Human RT2 RNA QC PCR Array. First strand cDNA synthesis was
performed with the RT2 first strand kit and qPCRwas carried out using the RT2 qPCR
master mix (Qiagen) as described above. Relative gene expression was determined by
the DDCT method using the web-based RT2 ProfilerTM PCR Array Data Analysis
software (SABiosciences). Data were normalised to the geometric mean of the house
keeping gene RPLP0.
Xenograft studies. Five to six week year old female CD1 and immunodeficient Swiss
nude mice were obtained from Harlan UK Ltd and Charles River UK Ltd,
respectively. Animals were maintained in individually ventilated caging systems in
groups of five at 19uC to 23uC, with a 12-hour light-dark cycle, and fed with a
conventional diet. All experiments were approved by the institutional Animal Care
and Use Committee of The School of Pharmacy London and experimental work was
carried out in accordance with UK Home Office regulations.
A dose-range assay was initially performed in female CD1 mice, with an initial
mean weight of 25 g. CL67 was dissolved in sterile dH2O and administered intra-
peritoneally to the mice (n 5 2). The body weight was recorded daily and the animals
were observed for clinical symptoms. The starting dose of 0.08 mg/kg was increased
step-wise up to 15 mg/kg. No adverse effects of CL67 were observed.
Pharmacodynamics of CL67 in 786-0 xenografts. 786-0 tumours were established in
the right flank of five to six weeks old immunodeficient Swiss nude mice, by
subcutaneous injection of 1 3 107 cells in a mixture of 50550 (v/v) medium and
MatrigelH (BD Bioscences). Tumour development was monitored by serial calliper
measurement. Four weeks after inoculation (median tumour volume 5 150 mm3)
animals were randomly assigned into 6 groups (n 5 4). One group was used as a
control (untreated) group and the rest of the mice were given CL67 intraperitoneally
at a dose of 15 mg/kg. Treated animals were sacrificed at 2 h, 4 h, 6 h, 8 h and 16 h
after injection. The tumour tissue was immediately excised and placed into 250 mL
Western Blotting lysis buffer (see immunoblotting method). The tissue was
homogenised on ice and incubated for a further 1 h on ice. The supernatant was then
collected by centrifugation (15,000 r.p.m., 10 min, 4uC) in a bench top centrifuge.
Supernatants were stored at 280uC until further processing for immunoblotting as
above.
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